Fuad El-Hibri, Who Led a Troubled Vaccine Maker, Dies at 64

His company, Emergent BioSolutions, won a lucrative contract to produce Covid vaccines but then had to throw out millions of contaminated doses.

Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims

The data have not yet been peer reviewed or published. But experts said the drug may give people with obesity an alternative to bariatric surgery.

How to Get Covid Treatments in New York City

Both antiviral treatments and monoclonal antibodies that treat Covid-19 are available across the city, but some public health experts worry that too few people know how to get them.

Lawmakers Dismiss McKinsey’s Apology on Opioid Crisis as ‘Empty’

The consulting firm’s top executive was apologetic before Congress but denied that advising both opioid manufacturers and their federal regulator posed a conflict of interest.

Should You Use Probiotics for Vaginal Health?

Pills and suppositories that promise to balance the vaginal microbiome are lining drugstore shelves and online marketplaces. But are they backed by science?

Vaccines for young children are being delayed by incomplete data, a top F.D.A. official suggests.

Moderna and the Pfizer-BioNTech partnership are developing versions of their coronavirus vaccines for children under 5, with emergency-use filings expected soon.

Congress Has to Ask How Much McKinsey Hurt the F.D.A.

Three critical questions to secure F.D.A. integrity.

Boss Trump, ‘the Sorest Loser of All Time’

Readers reflect on Donald Trump as both a party boss and a sore loser. Also: Reforming the patent system.

The Perils of Legalization

We answer a common reader question about the opioid crisis and legalizing drugs.

Masks … Off?

And information about antivirals, from Times reporters and readers.